INTRODUCTION

Ovarian cancer is the fifth most common cancer and the fourth most common cause of cancer death. It is commonly diagnosed after menopause. Epithelial ovarian cancer (EOC) represents approximately 90% of ovarian cancers. The standard treatment of EOC includes primary cytoreduction surgery, accompanied by a platinum-based chemotherapy.

Primary cytoreductive surgery is the primary treatment of EOC, and an optimal surgical outcome influences the prognosis of patients. Cytoreductive surgery can effectively excise the metastatic lesion, which is caused by transcoelomic spread in traditional view. However, recent reports have...
indicated that dissemination through lymph nodes and vessels may be of equal importance to the traditional route. Despite the definite advantage of cytoreductive surgery, the benefit of lymphadenectomy in EOC remains controversial, especially in different International Federation of Gynecology and Obstetrics (FIGO) stages.

Retrospective study has indicated that systematic lymphadenectomy can improve the 5-year overall survival (OS) in advanced-stage EOC, but not in the early stage or in patients with residual tumors ≤2 cm. Therefore, lymphadenectomy may only benefit the prognosis of ovarian cancer patients in advanced ovarian cancer patients with complete intraperitoneal debulking. Chan et al also demonstrated that in advanced EOC, the extent of lymphadenectomy affects the disease-specific survival benefit. However, a prospective clinical trial demonstrated that a systematic lymph node dissection had no OS benefit when compared with a selected lymphadenectomy in advanced EOC. In early-stage EOC, the data were also controversial. Contrary to Gao and Svolgaard, who supported that lymphadenectomy does not yield survival benefits in early-stage EOC, Chan found that lymphadenectomy was a significant prognostic factor for improved survival in stage I nonclear cell ovarian cancers.

Therefore, increasing attention has been paid to lymph node status, which can be evaluated by the number of resected lymph nodes (RLNs), lymph node ratio (LNR), and the log odds of positive lymph nodes (LODDS). Compared to a single parameter, LNR exhibits its advantage in breast, pancreatic, colon, and ovarian cancers. Another parameter, LODDS, showed superiority in predicting outcomes in breast, pancreatic, colorectal, and ovarian cancers.

Because the prior studies have been commonly limited by a small sample size, further studies are needed to explore the value of lymph node status in EOC patients with different stages. We performed a large population-based database investigation of the prognostic value of RLNs, LNR, and LODDS in ovarian cancer patients with different stages, which may decrease the selection biases that are associated with small sample size. In this study, 10 878 EOC patients with RLN information were analyzed to determine the different potential role of LNs, LNR, and LODDS.

2 METHODS

Demographic, clinicopathologic, and survival information were generated from the Surveillance, Epidemiology, and End Results (SEER) database (http://seer.cancer.gov/). All pathologically confirmed and surgically treated EOC patients from 1 January 1988 to 31 December 2013 were identified. The following were the inclusion criteria: (a) Lymph nodes status were available, (b) pathology limited to epithelial ovarian cancer, (c) only one primary cancer in the patient’s lifetime, (d) the primary site and morphology were ovarian, (e) survival time was available, and (f) grade was clear. A total of 10 878 patients were finally obtained. Patients were excluded if they had incomplete medical records, pathology, or outcome data.

Resected lymph nodes were used to evaluate lymphadenectomy extent, which were divided into six groups: one lymph node removed; two or three lymph nodes removed; four or five lymph nodes removed; six to 15 lymph nodes removed; 16-30 lymph nodes removed; and 31 or more lymph nodes removed. Lymph node status was characterized by LNR and LODDS. LNR is the ratio of positive lymph nodes (PLNs) to RLNs. LODDS is defined as the log of odds between PLNs and the number of negative nodes. LNR and LODDS were first divided into a lot of groups. Through analysis, we found that there was little difference among some classifications. We amalgamated these classifications. Finally, LNR was subdivided into three groups to meet proportionality assumptions: 0 to <10%, 10% to <40%, and 40%-100%. LODDS were grouped as follows: LODDS< –1.0, –1.0 ≤ LODDS<–0.5, –0.5 ≤ LODDS<0, LODDS≥0.

Survival was estimated by the Kaplan-Meier method and assessed by the log-rank test. OS was defined as the time between diagnosis and death due to any cause or censored at the last follow-up time if no events had occurred. Cancer-specific survival (CSS) was defined as the time between diagnosis and cancer-specific death. To investigate the significance of RLNs, LNR, and LODDS, multivariate analysis was performed using the Cox proportional hazards model after adjusting for other patient features, including age, race, tumor size, and grade in different FIGO stages. Analyses were performed using the SPSS statistical software package, version 19.0 (IBM Corporation, Armonk, NY, USA) and the R version 3.3.0 software (Institute for Statistics and Mathematics, Vienna, Austria; www.r-project.org). All tests were two-tailed, and statistical significance remained conventionally defined as P < 0.05 in all other cases.

3 RESULTS

The SEER dataset included 140 487 women who were diagnosed with ovarian cancer. A total of 113 276 women were excluded, 29 573 cases because ovarian cancer was not their first or only malignancy, 95 cases because the primary site was not ovarian, and/or morphology was not epithelial ovarian cancer, 514 cases due to borderline pathology, 20 015 patients with incomplete survival information, 53 535 cases because of pathology type, and 9544 women without grade information. As this study focused on analyzing lymph node status, 16 333 patients without information about lymph node
harvest were also excluded. Therefore, the final analysis comprised 10 878 cases (Figure 1).

Table 1 summarized the demographic and clinicopathologic characteristics according to the number of RLNs, LNR, and LODDS classification. The median patient age was 57.0 years (range: 15-96), 84.8% were Caucasian, and 51.8% had serous histology. The majority of patients were stage I (34.0%) or stage III (37.4%) at the time of surgery. A large proportion of patients had grade 3 disease (59.9%), with 14.4% and 25.7% of patients having grades 1 and 2 disease, respectively. The median survival time was 44 months (range: 0-311). The median number of RLNs in the entire cohort was 10 (range: 1-90). The number of patients with 1, 2-3, 4-5, 6-15, 16-30, and more than 31 RLNs was 1104 (10.1%), 1366 (12.6%), 1016 (9.8%), 3755 (34.5%), 2624 (24.1%), and 968 (8.9%), respectively. There were 5575 patients in the LODDS<−1 group, 2014 cases in −1 ≤ LODDS<−0.5, 1386 cases in −0.5 ≤ LODDS<0, and 1890 cases in LODDS≥0. Among all the patients, the majority of LNRs were in the 0-<10% (70.3%) group, with 11.3% in the 10% to <40% group, and 18.4% in 40%-100% group.

To evaluate the effect of the extent of lymph node dissection, our study cohort was divided into six groups: Patients who had 1, 2-3, 4-5, 6-15, 16-30, and ≥31 nodes were reported. We determined whether the influence of RLNs on CSS and OS was modified by FIGO stages. When FIGO stages were studied separately, the beneficial effect of lymphadenectomy with different extent was not observed for all FIGO stages (Table 2a; Figure 2). The results indicated that in FIGO stages II and III, an increasing numbers of lymph nodes were associated with a significant improvement in 5-y and 10-y CSS or OS. The findings of 1, 2-3, 4-5, 6-15, 16-30, and ≥31 lymph nodes were associated with 10-y OS of 37.1%, 41.3%, 63.5%, 60.9%, 67.7%, and 68.4% in FIGO II stage, and 17.6%, 22.4%, 23.0%, 28.0%, 29.9%, and 30.7% in FIGO III stage, respectively (P < 0.0001). However, for 3703 patients with stage I disease, the optimal survival rate was achieved in the 16-30 RLNs group, instead of the ≥31 group (OS: P = 0.0371; CSS: P = 0.0154). In 1658 EOC cases with stage IV, better OS was not found to be significantly associated with a more extensive lymphadenectomy (P = 0.0538).

The effects of LNR and LODDS are shown in Table 2b and Figure 3. The 5- and 10-y CSS and OS rates were found to be significantly decreased when more positive lymph nodes appeared within all FIGO stages. In an analysis of 5504 patients who had FIGO stages II and III disease, the 10-y OS was 61.2% for patients with an LNR of 0 to <10%, 53.1% for those with an LNR of 10% to <40%, and 18.5% for those with an LNR of 40%-100% (P < 0.0001). In FIGO II, the 10-y OS rates were 31.4%, 26.3%, and 16.4% for groups in which LNR was between 0 and 10%, between 10 and 40%, and more than 40%, respectively (P <0.0001). Notably, the 10-y OS rates in FIGO I were 81.0%, 68.1%, and 46.9% of three-category LNR (<0.0001), which indicated positive lymph nodes, especially the 0%-10% and 10%-40% groups, were more important in FIGO I. Additionally, the effect of LODDS was investigated in subgroups of patients with FIGO stages I-IV disease (Figure 4). Generally, a higher LODDS was significantly associated with poorer CSS (P < 0.0001) and OS (P < 0.0001). Nonetheless, differences exist in various FIGO stages. The four-category system is suitable for FIGO IV patients, with 10-y OS of 26.1%, 23.1%, 12.6%, and 9.9%, respectively. Three categories (LODDS<−1, −1 ≤ LODDS<0, and LODDS≥0) are compatible with FIGO stages I-III.
Table 1. Clinical and pathological characteristics of patients stratified by (a) the number of RLNs; (b) LNR and LODDS

|                               | Total number of resected lymph nodes | 1 node | 2-3 nodes | 4-5 nodes | 6-15 nodes | 16-30 nodes | ≥31 nodes |
|-------------------------------|----------------------------------------|--------|-----------|-----------|-----------|------------|----------|
|                               |                                         | No. (%)a | No. (%)a | No. (%)a | No. (%)a | No. (%)a | No. (%)a |
| Age                           |                                         |         |           |           |           |           |          |
| Mean                          |                                         | 59.7 ± 0.4| 58.8 ± 0.4| 57.8 ± 0.4| 57.0 ± 0.2| 56.3 ± 0.2| 54.9 ± 0.4| 57.2 ± 0.1|
| Median (range)                |                                         | 59.0 (16-91)| 59.0 (18-90)| 57.0 (18-96)| 56.0 (15-92)| 56.0 (16-90)| 54.5 (21-88)| 57.0 (15-96)|
| Tumor size                    |                                         |         |           |           |           |           |           |
| ≤1 cm                         |                                         | 27 (0.3%)| 23 (0.3%)| 14 (0.2%)| 77 (1.0%)| 68 (0.9%)| 15 (0.2%)| 224 (2.8%)|
| 1-5 cm                        |                                         | 152 (1.9%)| 201 (2.5%)| 143 (1.8%)| 536 (6.7%)| 383 (4.8%)| 161 (2.0%)| 1576 (19.8%)|
| 5-10 cm                       |                                         | 213 (2.7%)| 291 (3.6%)| 257 (3.2%)| 855 (10.7%)| 640 (8.0%)| 211 (2.6%)| 2467 (30.9%)|
| 10-20 cm                      |                                         | 271 (3.4%)| 367 (4.6%)| 304 (3.8%)| 1101 (13.8%)| 779 (9.8%)| 282 (3.5%)| 3104 (38.9%)|
| >20 cm                        |                                         | 48 (0.6%)| 62 (0.8%)| 59 (0.7%)| 228 (2.9%)| 153 (1.9%)| 54 (0.7%)| 604 (70.6%)|
| Race                          |                                         |         |           |           |           |           |           |
| Caucasians                    |                                         | 949 (8.7%)| 1129 (10.4%)| 880 (8.1%)| 3218 (29.6%)| 2230 (20.5%)| 819 (7.5%)| 9225 (84.8%)|
| Black                         |                                         | 75 (0.7%)| 105 (1.0%)| 67 (0.6%)| 171 (1.6%)| 104 (1.0%)| 29 (0.3%)| 551 (5.1%)|
| African                       |                                         | 13 (0.1%)| 10 (0.1%)| 9 (0.1%)| 16 (0.1%)| 6 (0.1%)| 6 (0.1%)| 60 (0.6%)|
| Asiansa                       |                                         | 63 (0.6%)| 114 (1.0%)| 95 (0.9%)| 325 (3.0%)| 256 (2.4%)| 104 (1.0%)| 957 (8.8%)|
| Pacific islander              |                                         | 4 (0.0%)| 6 (0.1%)| 4 (0.0%)| 16 (0.1%)| 15 (0.1%)| 6 (0.1%)| 51 (0.5%)|
| Othersb                       |                                         | 0 (0.0%)| 0 (0.0%)| 4 (0.0%)| 5 (0.0%)| 7 (0.1%)| 2 (0.0%)| 18 (0.2%)|
| Unknown                       |                                         | 0 (0.0%)| 2 (0.0%)| 2 (0.0%)| 4 (0.0%)| 6 (0.1%)| 2 (0.0%)| 16 (0.1%)|
| Stage of disease              |                                         |         |           |           |           |           |           |
| Stage I                       |                                         | 185 (1.7%)| 347 (3.2%)| 328 (3.0%)| 1439 (13.2%)| 1061 (9.8%)| 343 (3.2%)| 3703 (34.0%)|
| Stage II                      |                                         | 102 (0.9%)| 184 (1.7%)| 160 (1.5%)| 521 (4.8%)| 360 (3.3%)| 117 (1.1%)| 1444 (13.3%)|
| Stage III                     |                                         | 530 (4.9%)| 546 (5.0%)| 408 (3.8%)| 1309 (12.0%)| 893 (8.2%)| 383 (3.5%)| 4069 (37.4%)|
| Stage IV                      |                                         | 287 (2.6%)| 289 (2.7%)| 165 (1.5%)| 486 (4.5%)| 310 (2.8%)| 125 (1.1%)| 1662 (15.3%)|
| Grade of disease              |                                         |         |           |           |           |           |           |
| Grade 1                       |                                         | 95 (0.9%)| 166 (1.5%)| 157 (1.4%)| 595 (5.5%)| 410 (3.8%)| 145 (1.3%)| 1568 (14.4%)|
| Grade 2                       |                                         | 259 (2.4%)| 332 (3.1%)| 260 (2.4%)| 1019 (9.4%)| 696 (6.4%)| 225 (2.1%)| 2791 (25.7%)|
| Grade 3                       |                                         | 750 (6.9%)| 868 (8.0%)| 644 (5.9%)| 2141 (19.7%)| 1518 (14.0%)| 598 (5.5%)| 6519 (59.9%)|
| Histology                     |                                         |         |           |           |           |           |           |
| Serous                        |                                         | 732 (6.7%)| 807 (7.4%)| 565 (5.2%)| 1828 (16.8%)| 1232 (11.3%)| 475 (4.4%)| 5639 (51.8%)|

(Continues)
Table 1. (Continued)

(a)

| Total number of resected lymph nodes | 1 node | 2-3 nodes | 4-5 nodes | 6-15 nodes | 16-30 nodes | ≥31 nodes | Total |
|--------------------------------------|--------|-----------|-----------|------------|-------------|-----------|-------|
| Clear cell                           | 75 (0.7%) | 115 (1.1%) | 114 (1.0%) | 456 (4.2%) | 365 (3.3%) | 125 (1.1%) | 1249 (11.5%) |
| Mucinous                             | 69 (0.6%) | 101 (0.9%) | 78 (0.7%) | 342 (3.1%) | 180 (1.7%) | 65 (0.6%) | 835 (7.7%) |
| Endometrioid                         | 205 (1.9%) | 323 (3.0%) | 275 (2.5%) | 1051 (9.7%) | 806 (7.4%) | 282 (2.6%) | 2942 (27.1%) |
| Carcinosarcoma                       | 12 (0.1%) | 8 (0.1%) | 13 (0.1%) | 35 (0.3%) | 28 (0.3%) | 13 (0.1%) | 109 (1.0%) |
| Undifferentiated                     | 11 (0.1%) | 12 (0.1%) | 16 (0.1%) | 43 (0.4%) | 14 (0.1%) | 8 (0.1%) | 104 (1.0%) |

(b)

| LNR | 0%-10% | 10%-40% | 40%-100% | LODDS | LODDS<-1 | -1 ≤ LODDS<-0.5 | -0.5 ≤ LODDS<0 | LODDS≥0 | Total |
|-----|--------|---------|----------|-------|-----------|-----------------|----------------|---------|-------|
| Age |        |         |          | Mean  | 56.5 ± 0.1 | 57.9 ± 0.4 | 59.7 ± 0.3 | 55.8 ± 0.2 | 57.8 ± 0.3 | 58.5 ± 0.3 | 59.8 ± 0.4 | 57.2 ± 0.1 |
|     | Median (range) | 56.0 (15-96) | 58.0 (17-89) | 60.0 (17-91) | 55.0 (15-96) | 58.0 (18-90) | 58.0 (16-91) | 59.0 (17-91) | 57.0 (15-96) |
| Tumor size |        |         |          | ≤1 cm | 177 (2.2%) | 19 (0.2%) | 28 (0.4%) | 135 (1.7%) | 34 (0.4%) | 29 (0.4%) | 26 (0.3%) | 224 (2.8%) |
|     |        |         |          | 1-5 cm | 1077 (13.5%) | 186 (2.3%) | 312 (3.9%) | 793 (9.9%) | 280 (3.5%) | 210 (2.6%) | 292 (3.7%) | 1575 (19.8%) |
|     |        |         |          | 5-10 cm | 1691 (21.2%) | 293 (3.7%) | 481 (6.0%) | 1261 (15.8%) | 455 (5.7%) | 293 (3.7%) | 456 (5.7%) | 2465 (30.9%) |
|     |        |         |          | 10-20 cm | 2391 (30.0%) | 289 (3.6%) | 422 (5.3%) | 1794 (22.5%) | 556 (7.0%) | 349 (4.4%) | 403 (5.0%) | 3102 (38.9%) |
|     |        |         |          | >20 cm | 508 (6.4%) | 48 (0.6%) | 48 (0.6%) | 389 (4.9%) | 102 (1.3%) | 69 (0.9%) | 44 (0.5%) | 604 (7.6%) |
| Race |        |         |          | Caucasians | 6440 (59.3%) | 1056 (9.7%) | 1718 (15.8%) | 4715 (43.4%) | 1691 (15.6%) | 1184 (10.9%) | 1624 (14.9%) | 9214 (84.8%) |
|     |        |         |          | Black | 349 (3.2%) | 81 (0.7%) | 120 (1.1%) | 208 (1.9%) | 131 (1.2%) | 96 (0.9%) | 115 (1.1%) | 550 (5.1%) |
|     |        |         |          | African | 35 (0.3%) | 12 (0.1%) | 13 (0.1%) | 22 (0.2%) | 12 (0.1%) | 14 (0.1%) | 12 (0.1%) | 60 (0.6%) |
|     |        |         |          | Asians | 742 (6.8%) | 77 (0.7%) | 137 (1.3%) | 571 (5.3%) | 168 (1.5%) | 88 (0.8%) | 129 (1.2%) | 956 (8.8%) |
|     |        |         |          | Pacific islander | 41 (0.4%) | 3 (0.0%) | 7 (0.1%) | 35 (0.3%) | 5 (0.0%) | 4 (0.0%) | 7 (0.0%) | 51 (0.5%) |
|     |        |         |          | Others | 16 (0.1%) | 0 (0.0%) | 2 (0.0%) | 12 (0.1%) | 4 (0.0%) | 0 (0.0%) | 2 (0.0%) | 18 (0.2%) |
|     |        |         |          | Unknown | 15 (0.1%) | 0 (0.0%) | 1 (0.0%) | 12 (0.1%) | 3 (0.0%) | 0 (0.0%) | 1 (0.0%) | 16 (0.1%) |

(Continues)
| FIGO stage of disease | LNR | | | LODDS | | | | | | Total |
|-----------------------|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|
|                       | 0%-10% | 10%-40% | 40%-100% | LODDS<-1 | -1 ≤ LODDS<-0.5 | -0.5 ≤ LODDS<0 | LODDS≥0 |       |
| Stage I               | 3666 (33.7%) | 29 (0.3%) | 8 (0.1%) | 2975 (27.4%) | 525 (4.8%) | 195 (1.8%) | 8 (0.1%) | 3703 (34.1%) |
| Stage II              | 1344 (12.4%) | 37 (0.3%) | 59 (0.5%) | 1015 (9.3%) | 267 (2.5%) | 101 (0.9%) | 57 (0.6%) | 1440 (13.3%) |
| Stage III             | 1997 (18.4%) | 859 (7.9%) | 1208 (11.1%) | 1263 (11.6%) | 906 (8.3%) | 761 (7.0%) | 1134 (9.5%) | 4064 (37.4%) |
| Stage IV              | 631 (5.8%) | 304 (2.8%) | 723 (6.7%) | 322 (3.0%) | 316 (2.9%) | 329 (3.0%) | 691 (6.4%) | 1658 (15.3%) |

| Grade of disease |       |       |       |       |       |       |       |       |       |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Grade 1          | 1424 (13.1%) | 76 (0.7%) | 67 (0.6%) | 114 (10.3%) | 272 (2.5%) | 118 (1.1%) | 63 (0.5%) | 1567 (14.4%) |
| Grade 2          | 2241 (20.6%) | 205 (1.9%) | 342 (3.1%) | 1664 (15.3%) | 497 (4.6%) | 313 (2.9%) | 314 (2.9%) | 2788 (25.7%) |
| Grade 3          | 3973 (36.6%) | 948 (8.7%) | 1589 (14.6%) | 2797 (25.7%) | 1245 (11.5%) | 955 (8.8%) | 1513 (5.2%) | 6510 (59.9%) |

| Histology |       |       |       |       |       |       |       |       |       |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Serous    | 3054 (28.1%) | 930 (8.6%) | 1644 (15.1%) | 1987 (18.3%) | 1127 (10.4%) | 966 (8.8%) | 1548 (14.3%) | 5628 (51.8%) |
| Clear cell| 1066 (9.8%) | 90 (0.8%) | 93 (0.9%) | 869 (8.0%) | 192 (1.8%) | 97 (0.9%) | 91 (0.8%) | 1249 (11.5%) |
| Mucinous  | 760 (7.0%) | 38 (0.3%) | 37 (0.3%) | 576 (5.3%) | 154 (1.4%) | 71 (0.7%) | 34 (0.3%) | 835 (7.7%) |
| Endometriod| 2626 (24.1%) | 136 (1.2%) | 178 (1.6%) | 2056 (18.9%) | 490 (4.6%) | 221 (2.0%) | 173 (1.5%) | 2940 (27.1) |
| Carcinosarcoma| 75 (0.7%) | 15 (0.1%) | 19 (0.2%) | 50 (0.5%) | 27 (0.2%) | 14 (0.1%) | 18 (0.2%) | 109 (1.0%) |
| Undifferentiated | 57 (0.5%) | 20 (0.2%) | 27 (0.2%) | 37 (0.3%) | 24 (0.2%) | 17 (0.2%) | 26 (0.3%) | 104 (1.0%) |

*aAsians were defined as Chinese, Japanese, Korean, Vietnamese, and Filipino.

*bOthers were defined as all other race/ethnicity parameters.
Table 2. Cancer-specific and overall survival according to (a) the number of RLNs in different FIGO stages; (b) LNR and LODDS in different FIGO stages

(a)

| The number of RLNs | 1 node | 2-3 nodes | 4-5 nodes | 6-15 nodes | 16-30 nodes | ≥31 nodes | P value |
|--------------------|--------|-----------|-----------|------------|-------------|-----------|---------|
| FIGO stage I       |        |           |           |            |             |           |         |
| 5-year CSS         | 87.5%  | 91.1%     | 89.3%     | 92.4%      | 95.6%       | 89.9%     | 0.0033  |
| 10-year CSS        | 81.0%  | 86.7%     | 85.3%     | 86.9%      | 90.8%       | 85.4%     |         |
| 5-year OS          | 84.8%  | 89.0%     | 87.3%     | 90.4%      | 93.5%       | 88.9%     | 0.0003  |
| 10-year OS         | 70.4%  | 77.3%     | 77.4%     | 80.8%      | 86.4%       | 78.3%     |         |
| FIGO stage II      |        |           |           |            |             |           |         |
| 5-year CSS         | 58.1%  | 71.8%     | 81.3%     | 80.1%      | 81.3%       | 87.4%     | <0.0001 |
| 10-year CSS        | 45.2%  | 47.7%     | 68.5%     | 67.6%      | 72.2%       | 70.4%     |         |
| 5-year OS          | 56.4%  | 68.5%     | 75.4%     | 78.6%      | 79.3%       | 84.8%     | <0.0001 |
| 10-year OS         | 37.1%  | 41.3%     | 63.5%     | 60.9%      | 67.7%       | 68.4%     |         |
| FIGO stage III     |        |           |           |            |             |           |         |
| 5-year CSS         | 36.9%  | 41.7%     | 43.1%     | 50.2%      | 52.9%       | 54.9%     | <0.0001 |
| 10-year CSS        | 19.5%  | 25.6%     | 25.9%     | 31.1%      | 32.9%       | 32.6%     |         |
| 5-year OS          | 35.5%  | 39.7%     | 41.9%     | 47.9%      | 50.4%       | 52.5%     | <0.0001 |
| 10-year OS         | 17.6%  | 22.4%     | 23.0%     | 28.0%      | 29.9%       | 30.7%     |         |
| FIGO stage IV      |        |           |           |            |             |           |         |
| 5-year CSS         | 22.4%  | 30.7%     | 28.1%     | 27.2%      | 32.3%       | 32.3%     | 0.0390  |
| 10-year CSS        | 10.1%  | 15.5%     | 14.1%     | 15.2%      | 22.5%       | 24.7%     |         |
| 5-year OS          | 21.4%  | 29.3%     | 27.1%     | 26.2%      | 30.5%       | 31.1%     | 0.0538  |
| 10-year OS         | 8.6%   | 12.4%     | 13.6%     | 14.3%      | 19.2%       | 21.6%     |         |

(b)

| LNR (%) | 0-10 | 10-40 | 40-100 | P value | LODDS (%) | LODDS<−1 | −1≤LODDS<−0.5 | −0.5≤LODDS<0 | LODDS≥0 | P value |
|---------|------|-------|--------|---------|-----------|----------|-------------|--------------|---------|---------|
| FIGO stage I |      |       |        |         |           |          |             |              |         |         |
| 5-year CSS | 92.7 | 72.1  | 46.9   | <0.0001 | 93.4      | 89.9     | 87.1        | 46.9         |         | <0.0001 |
| 10-year CSS | 87.6 | 68.1  | 46.9   |         | 88.4      | 84.9     | 81.2        | 46.9         |         |         |
| 5-year OS | 90.8 | 62.1  | 37.5   | <0.0001 | 91.7      | 86.9     | 84.0        | 45.0         |         | <0.0001 |
| 10-year OS | 81.0 | 58.6  | 25.0   |         | 82.8      | 75.8     | 70.8        | 30.0         |         |         |

(Continues)
| FIGO stage II          | 5-year CSS | 10-year CSS | 10-50 | 40-100 | P value | LODDS (%) | 5-50 | 10-50 | 40-100 | 5-50 | 10-50 | 40-100 | P value |
|------------------------|------------|-------------|-------|--------|---------|-----------|------|-------|--------|------|-------|--------|---------|
| 5-year CSS             | 80.5       | 70.3        | 38.6  | <0.0001| 82.7    | 77.1      | 65.9 | 36.3  | <0.0001| 82.7 | 77.1  | 65.9   | 36.3  | <0.0001|
| 10-year CSS            | 67.3       | 59.0        | 19.9  |         | 71.2    | 58.1      | 52.7 | 19.1  |         | 71.2 | 58.1  | 52.7   | 19.1  |         |
| 5-year OS              | 78.0       | 70.3        | 38.7  | <0.0001| 80.7    | 72.6      | 64.9 | 36.7  | <0.0001| 80.7 | 72.6  | 64.9   | 36.7  | <0.0001|
| 10-year OS             | 61.2       | 53.1        | 18.5  |         | 66.1    | 49.9      | 43.9 | 19.2  |         | 66.1 | 49.9  | 43.9   | 19.2  |         |
| FIGO stage III         |            |             |       |         |         |           |      |       |         |      |       |         |        |
| 5-year CSS             | 54.3       | 49.0        | 35.0  | <0.0001| 58.4    | 52.0      | 43.1 | 34.5  | <0.0001| 58.4 | 52.0  | 43.1   | 34.5  | <0.0001|
| 10-year CSS            | 34.0       | 29.1        | 19.1  |         | 37.5    | 30.9      | 26.3 | 18.1  |         | 37.5 | 30.9  | 26.3   | 18.1  |         |
| 5-year OS              | 52.5       | 46.6        | 32.8  | <0.0001| 56.5    | 49.9      | 41.1 | 32.5  | <0.0001| 56.5 | 49.9  | 41.1   | 32.5  | <0.0001|
| 10-year OS             | 31.4       | 26.3        | 16.4  |         | 34.7    | 28.0      | 24.2 | 15.4  |         | 34.7 | 28.0  | 24.2   | 15.4  |         |
| FIGO stage IV          |            |             |       |         |         |           |      |       |         |      |       |         |        |
| 5-year CSS             | 39.5       | 29.4        | 18.1  | <0.0001| 41.9    | 38.5      | 26.1 | 18.6  | <0.0001| 41.9 | 38.5  | 26.1   | 18.6  | <0.0001|
| 10-year CSS            | 24.0       | 15.0        | 9.4   |         | 26.1    | 23.1      | 12.6 | 9.5   |         | 26.1 | 23.1  | 12.6   | 9.5   |         |
| 5-year OS              | 37.8       | 28.6        | 17.0  | <0.0001| 39.8    | 37.2      | 25.5 | 17.6  | <0.0001| 39.8 | 37.2  | 25.5   | 17.6  | <0.0001|
| 10-year OS             | 20.2       | 13.9        | 8.2   |         | 26.1    | 23.1      | 12.6 | 9.9   |         | 26.1 | 23.1  | 12.6   | 9.9   |         |

Significant values are in bold.
Figure 2. Kaplan-Meier analysis of overall survival of RLNs according to FIGO stages.
Figure 3. Kaplan-Meier analysis of overall survival of LNR according to FIGO stages
Figure 4. Kaplan-Meier analysis of overall survival of LODDS according to FIGO stages.
On multivariate analysis, LNR persisted as a significant and independent prognostic factor of OS (Table 3a) and CSS (Table 3b), regardless of the stage of the disease. The hazard ratios (HRs) of LNR on OS in FIGO stages I-IV were 2.569, 1.670, 1.234, and 1.259, respectively. LODDS was also a significant prognostic factor, which was associated with a poorer CSS and OS.

In contrast, the number of lymph nodes resected was a significant prognostic factor only for FIGO I-III on OS (HR: 0.895, 95% confidence interval [CI]: 0.827-0.969 in stage I; HR: 0.818, 95% CI: 0.757-0.884 in stage II; HR: 0.949, 95% CI: 0.917-0.982 in stage III; P < 0.001) and CSS (HR: 0.899, 95% CI: 0.814-0.993 in stage I; HR: 0.833, 95% CI: 0.763-0.910 in stage II; HR: 0.947, 95% CI: 0.915-0.981 in stage III; P < 0.001). In FIGO IV patients, RLNs had no significant effect on CSS (HR: 0.968, 95% CI: 0.921-0.993, P = 0.200) and OS (HR: 0.966, 95% CI: 0.920-1.014, P = 0.165), suggesting that not all stages of patients could benefit from lymphadenectomy. In addition, multivariate analysis also indicated that age and grade were significant prognostic factors for OS (Table 3) and CSS (Table 4).

### 4 | DISCUSSION

Ovarian cancer is the most common cancer and has the highest death rate in female malignancy. Although surgery is definitely necessary in the treatment of EOC, the role of lymphadenectomy is controversial. In the present study, we investigated the prognostic value of RLNs, LNR, and LODDS in EOC patients with different disease stages. Our results showed that in different stages, the prognostic value of lymph node parameters was in conformity. In FIGO stage II and III, an increasing number of RLNs was associated with a significant improvement in survival. However, for stage I disease, the optimal survival rate was achieved in the 16-30 RLNS group, and in stage IV patients, a more extensive lymphadenectomy did not yield survival benefits. In all disease stages, a higher LNR and LODDS were significantly associated with poorer survival. Furthermore, the two-category system of LNR was suitable for FIGO stage II and III patients, and the three-category system was suitable for FIGO I and IV patients. Three LODDS categories (LODDS<-1, -1 ≤ LODDS<0, and LODDS≥0) were compatible with FIGO I-III disease. However, for FIGO IV patients, the four-category system (LODDS<-1, -1 ≤ LODDS<0.5, -0.5 ≤ LODDS<0, and LODDS≥0) is more suitable. Multivariate analysis demonstrated that LODDS and LNR were significant independent prognostic factors regardless of the disease stage, but not RLN classification.

Compared to the previous FIGO staging system, the revised FIGO staging system utilizes PLNs to characterize stage III. However, because PLNs is not reflex the information of negative lymph nodes, it is not appropriate to make predictions. LNR, combining positive lymph nodes and resected number, should be utilized to reduce the potential bias. In stage IIIC ovarian cancer patients with lymphadenectomy, increasing LNR leads to significantly decreased OS, which was similar to the results of our study. In our study, we demonstrated that, in FIGO stage III patients, LNR within 0 to ≤40% group had survival advantage over LNR more than 40% group. Furthermore, this two-category system is also suitable for stage II disease. However, due to the significant difference of survival between LNR>0 to ≤10% and LNR>10 to ≤40%, dividing LNR into three parts (0 to ≤10%, 10% to ≤40%, and >40%) was more suitable in FIGO stage IV. Because the positive nodes were more common in advanced-stage disease, studies about LNRs have always been focused on those patients. Therefore, the role of LNR in early-stage disease was ambiguous. Our research demonstrated that classifying LNR into three parts (0 to ≤10%, 10% to ≤40%, and >40%) was associated with decreased OS in FIGO stage I. Based on these findings, our study recommends the adaptation of the two-category system of LNR in FIGO stage II and III, and the three-category system in FIGO stage I and IV. Through this method, the survival status of patients can be predicted more accurately.

Log odds of positive lymph nodes, as an emerging indicator of lymph node status, has been studied in various cancers. Little is known about the role of LODDS in ovarian cancer. Xu et al found LODDS as an independent prognostic factor for predicting survival in patients with EOC regardless of the tumor stage. Although LODDS exhibits discriminatory ability in predicting survival, there is no study concerning the diverse role of LODDS in different FIGO stages. Our study demonstrated that in FIGO stage I to III patients, the three classification method (LODDS<-1, -1 ≤ LODDS<0, and LODDS≥0) could stratify patients clearly. However, in FIGO IV, classification of LODDS into four categories is more suitable for prediction.

The therapeutic value of lymphadenectomy in ovarian cancer remains controversial. In early stages, survival of patients with lymph node dissection was significantly better than that of patients without lymph node dissection, whereas, Maggioni et al reported that, in FIGO stage I-II patients, there was no difference between women undergoing a node sampling and those who underwent a lymphadenectomy. In our study, we found that lymphadenectomy had diverse effects on stage I and II disease. In FIGO stage I, a large number of resected lymph nodes did not represent a better outcome. The patients with 16-30 RLNs have the best prognosis. When RLNs numbered more than 30, the survival rate decreased. In FIGO stage II, the minimum number of RLNS for a good prognosis is 4, preferably up to 16. According to our study, in early-stage ovarian cancer, the goal of the extent of lymphadenectomy is to remove 16-30 lymph nodes. In advanced-stage lymphadenectomy, there were also several opinions. Pereira reported that removing
| Prognostic factor | FIGO I Hazard ratio | 95% confidence interval | P | FIGO II Hazard ratio | 95% confidence interval | P | FIGO III Hazard ratio | 95% confidence interval | P | FIGO IV Hazard ratio | 95% confidence interval | P |
|------------------|---------------------|-------------------------|---|---------------------|-------------------------|---|---------------------|-------------------------|---|---------------------|-------------------------|---|
| Race             | 1.106               | 1.003-1.221             | **0.044** | 0.914               | 0.808-1.034             | 0.152 | 0.999               | 0.936-1.065             | 0.969 | 0.965               | 0.879-1.060             | 0.458 |
| Age              | 1.274               | 1.223-1.328             | **0.000** | 1.139               | 1.089-1.191             | **0.000** | 1.097               | 1.074-1.120             | **0.000** | 1.069               | 1.036-1.104             | **0.000** |
| Grade            | 1.296               | 1.126-1.492             | **0.000** | 1.376               | 1.160-1.632             | **0.000** | 1.338               | 1.215-1.474             | **0.000** | 1.185               | 1.012-1.389             | **0.035** |
| Tumor size       | 1.047               | 1.020-1.075             | **0.001** | 1.011               | 0.982-1.041             | 0.464 | 0.988               | 0.975-1.001             | 0.062 | 1.005               | 0.986-1.025             | 0.608 |
| RLNs             | 0.895               | 0.827-0.969             | **0.006** | 0.818               | 0.757-0.884             | **0.000** | 0.949               | 0.917-0.982             | **0.002** | 0.966               | 0.920-1.014             | 0.165 |
| LNR              | 2.569               | 1.766-3.737             | **0.000** | 1.671               | 1.385-2.017             | **0.000** | 1.234               | 1.163-1.310             | **0.000** | 1.295               | 1.191-1.408             | **0.000** |
| LODDS            | 1.423               | 1.229-1.647             | **0.000** | 1.499               | 1.358-1.654             | **0.000** | 1.184               | 1.141-1.230             | **0.000** | 1.174               | 1.114-1.238             | **0.000** |

(a) The bold values present p < 0.05.

| Prognostic factor | FIGO I Hazard ratio | 95% confidence interval | P | FIGO II Hazard ratio | 95% confidence interval | P | FIGO III Hazard ratio | 95% confidence interval | P | FIGO IV Hazard ratio | 95% confidence interval | P |
|------------------|---------------------|-------------------------|---|---------------------|-------------------------|---|---------------------|-------------------------|---|---------------------|-------------------------|---|
| Race             | 1.074               | 0.952-1.211             | 0.244 | 0.883               | 0.767-1.018             | 0.086 | 0.995               | 0.931-1.063             | 0.878 | 0.955               | 0.867-1.052             | 0.353 |
| Age              | 1.122               | 1.066-1.181             | **0.000** | 1.074               | 1.021-1.129             | **0.005** | 1.082               | 1.059-1.105             | **0.000** | 1.065               | 1.032-1.099             | **0.000** |
| Grade            | 1.664               | 1.387-1.996             | **0.000** | 1.453               | 1.195-1.768             | **0.000** | 1.377               | 1.245-1.524             | **0.000** | 1.188               | 1.009-1.399             | **0.039** |
| Tumor size       | 1.040               | 1.007-1.074             | **0.017** | 1.009               | 0.976-1.043             | 0.591 | 0.985               | 0.972-0.999             | **0.032** | 1.002               | 0.982-1.022             | 0.860 |
| RLNs             | 0.899               | 0.814-0.993             | **0.036** | 0.833               | 0.763-0.910             | **0.000** | 0.947               | 0.915-0.981             | **0.003** | 0.968               | 0.921-1.017             | 0.200 |
| LNR              | 2.589               | 1.632-4.080             | **0.000** | 1.836               | 1.504-2.242             | **0.000** | 1.221               | 1.148-1.298             | **0.000** | 1.337               | 1.227-1.456             | **0.000** |
| LODDS            | 1.418               | 1.178-1.706             | **0.000** | 1.561               | 1.402-1.739             | **0.000** | 1.182               | 1.137-1.229             | **0.000** | 1.186               | 1.124-1.252             | **0.000** |

(b) The bold values present p < 0.05.
more than 40 lymph nodes may yield survival benefit. Iwase, however, indicated that systematic lymphadenectomy did not confer therapeutic benefits, which is similar to our results in FIGO stage IV. In FIGO III, we suggest that the number of RLNs should be more than 6.

In conclusion, our data suggest that the prognostic information provided by LNRs or LODDS should be deciphered according to patients’ FIGO stage. Flexible application of LNR or LODDS in different FIGO stages to characterize ovarian cancer patients might predict outcomes more precisely. Furthermore, taking FIGO stage into consideration when carrying out lymphadenectomy may avoid a lack of benefit in patients with ovarian cancer, which can further contribute to the individualized clinical decision. To prevent the bias inherent to the retrospective methodology, the results of this study need to be confirmed in future prospective studies.

ACKNOWLEDGMENTS

This work was supported by grants from the Natural Science Foundation of Shanghai (NO. 17ZR1403500) and Shanghai Sailing Program (NO. 16YF1401100).

CONFLICT OF INTEREST

None declared.

ORCID

Xin Lu http://orcid.org/0000-0003-1639-9549

REFERENCES

1. Hoffman BL, Schorge JO, Schaffer JI, et al. Epithelial ovarian cancer. Williams gynecology (2nd edn). McGraw-Hill Professional Publishing: McGraw Hill Medical; 2012:853-878.
2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
3. Matsuo K, Yoshino K, Hasegawa K, et al. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecol Oncol. 2015;136:198-204.
4. Matsuo K, Sheridan TB, Yoshino K, et al. Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med. 2012;1:156-164.
5. Matsuo K, Sheridan TB, Mabuchi S, et al. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014;133:473-479.
6. Li J, Li S, Chen R, et al. Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. Oncotarget. 2017;8:9672-9685.
7. Mikami M. Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol. 2014;25:279-281.
8. Dell’Anna T, Signorelli M, Benedetti-Panici P, et al. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial. Br J Cancer. 2012;107:785-792.
9. Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. 2015;45:49-60.
10. du Bois A, Reuss A, Harter P, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733-1739.
11. Chan JK, Urban R, Hu JM, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. 2007;96:1817-1822.
12. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560-566.
13. Svolgaard O, Lidegaard O, Nielsen ML, et al. Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2014;93:256-260.
14. Chan JK, Munro EG, Cheung MK, et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007;109:12-19.
15. Kleppe M, van der Aa MA, Van Gorp T, et al. The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer. Eur J Cancer. 2016;66:83-90.
16. Ataseven B, Grimm C, Harter P, et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135:435-440.
17. Mahdi H, Thrall M, Kumar S, et al. The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patients. J Surg Oncol. 2011;103:724-729.
18. Zhou J, He ZY, Li FY, et al. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study. Oncotarget. 2016;7:7952-7959.
19. La Torre M, Nigri G, Petrucciani N, et al. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes. Panreatology. 2014;14:289-294.
20. Chen LJ, Chung KP, Chang YJ, et al. Ratio and log odds of positive lymph nodes in breast cancer patients with mastectomy. Surg Oncol. 2015;24:239-247.
21. Riediger H, Kulemann B, Wittel U, et al. Prognostic role of log odds of lymph nodes after resection of pancreatic head cancer. J Gastrointest Surg. 2016;20:1707-1715.
22. Song YX, Gao P, Wang ZN, et al. Which is the most suitable classification for colorectal cancer, log odds, the number or the ratio of positive lymph nodes? PLoS ONE. 2011;6:e28937.
23. Ozawa T, Ishihara S, Sunami E, et al. Log odds of positive lymph nodes as a prognostic indicator in stage IV colorectal cancer patients undergoing curative resection. J Surg Oncol. 2015;111:465-471.
24. Xu XL, Cheng H, Tang MS, et al. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer. Oncotarget. 2016;8(5):8120-8130.
25. Wen J, Yang Y, Liu P, et al. Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast. 2017;33:14-22.
26. Tsai J, Bertoni D, Hernandez-Boussard T, et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. *Ann Surg Oncol*. 2016;23:3310-3316.

27. Liu D, Chen Y, Deng M, et al. Lymph node ratio and breast cancer prognosis: a meta-analysis. *Breast Cancer*. 2014;21:1-9.

28. Liao GS, Chou YC, Golshan M, et al. Prognostic value of the lymph node ratio in breast cancer subtypes. *Am J Surg*. 2015;210:749-754.

29. Sugimoto K, Sakamoto K, Tomiki Y, et al. Proposal of new classification for stage III colon cancer based on the lymph node ratio: analysis of 4,172 patients from multi-institutional database in Japan. *Ann Surg Oncol*. 2015;22:528-534.

30. Parnaby CN, Scott NW, Ramsay G, et al. Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection. *Br J Cancer*. 2015;113:212-219.

31. Lee HY, Choi HJ, Park KJ, et al. Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. *Ann Surg Oncol*. 2007;14:1712-1717.

32. Chen SL, Steele SR, Eberhardt J, et al. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. *Ann Surg*. 2011;253:82-87.

33. Prat J. Ovarian, fallopian tube and peritoneal cancer staging: Rationale and explanation of new FIGO staging 2013. *Best Pract Res Clin Obstet Gynaecol*. 2015;29:858-869.

34. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. *Arch Gynecol Obstet*. 2014;290:839-842.

35. Bachmann C, Brucker SY, Kraemer B, et al. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer. *J Cancer Res Clin Oncol*. 2015;141:1475-1480.

36. Ulker V, Kuru O, Numanoglu C, et al. Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience. *Arch Gynecol Obstet*. 2014;289:1087-1092.

37. Maggioni A, Benedetti Panici P, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. *Br J Cancer*. 2006;95:699-704.

38. Pereira A, Perez-Medina T, Magrina JF, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. *Br J Cancer*. 2012;95:2987-2992.

39. Iwase H, Takada T, Iitsuka C, et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. *J Gynecol Oncol*. 2015;26:303-310.

**How to cite this article:** Wang J, Li J, Chen R, Lu X. Survival effect of different lymph node staging methods on ovarian cancer: An analysis of 10 878 patients. *Cancer Med*. 2018;7:4315–4329. [https://doi.org/10.1002/cam4.1680](https://doi.org/10.1002/cam4.1680)